OSE Immunotherapeutics S.A.
OSE.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €113,021 | €155,352 | €133,600 | €88,468 |
| - Cash | €25,394 | €16,745 | €75,746 | €18,672 |
| + Debt | €38,664 | €46,132 | €43,884 | €45,801 |
| Enterprise Value | €126,291 | €184,739 | €101,738 | €115,597 |
| Revenue | €1,323 | €831 | €82,573 | €869 |
| % Growth | 59.2% | -99% | 9,402.1% | – |
| Gross Profit | €0 | €862 | €69,046 | €869 |
| % Margin | 0% | 103.7% | 83.6% | 100% |
| EBITDA | -€14,848 | -€19,442 | €60,637 | -€11,701 |
| % Margin | -1,122.3% | -2,339.6% | 73.4% | -1,346.5% |
| Net Income | -€15,105 | -€19,730 | €57,175 | -€11,143 |
| % Margin | -1,141.7% | -2,374.2% | 69.2% | -1,282.3% |
| EPS Diluted | -0.68 | -0.91 | 2.63 | -0.54 |
| % Growth | 25.3% | -134.6% | 587% | – |
| Operating Cash Flow | -€17,982 | -€18,193 | €66,633 | -€8,037 |
| Capital Expenditures | -€9 | -€59 | -€18 | -€16 |
| Free Cash Flow | -€17,991 | -€18,252 | €66,615 | -€8,053 |